Want to see JP:4521 full AI Analyst Report?
Kaken Pharmaceutical Co (4521) Financial Statements
0 Followers
Kaken Pharmaceutical Co Financial Overview
Kaken Pharmaceutical Co's market cap is currently ¥136.15B. The company's EPS TTM is ¥333.12; its P/E ratio is 13.90; and it has a dividend yield of 5.08%. Kaken Pharmaceutical Co is estimated to report earnings on November 9, 2026, and the estimated EPS forecast is ¥-5.29. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ¥ 94.03B | ¥ 76.87B | ¥ 72.04B | ¥ 72.98B | ¥ 76.03B |
| Gross Profit | ¥ 58.26B | ¥ 39.24B | ¥ 38.54B | ¥ 39.56B | ¥ 41.58B |
| Operating Income | ¥ 21.04B | ¥ -899.00M | ¥ 9.51B | ¥ 8.00B | ¥ 17.06B |
| EBITDA | ¥ 22.02B | ¥ 5.68B | ¥ 12.57B | ¥ 9.40B | ¥ 16.38B |
| Net Income | ¥ 13.95B | ¥ 2.14B | ¥ 8.03B | ¥ 5.44B | ¥ 9.55B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ¥ 70.08B | ¥ 50.70B | ¥ 65.32B | ¥ 74.26B | ¥ 74.62B |
| Total Assets | ¥ 190.42B | ¥ 178.22B | ¥ 171.62B | ¥ 166.33B | ¥ 165.18B |
| Total Debt | ¥ 3.85B | ¥ 3.85B | ¥ 3.85B | ¥ 3.85B | ¥ 3.85B |
| Net Debt | ¥ -50.24B | ¥ -40.86B | ¥ -46.77B | ¥ -55.71B | ¥ -57.17B |
| Total Liabilities | ¥ 37.78B | ¥ 30.59B | ¥ 27.87B | ¥ 29.49B | ¥ 26.85B |
| Stockholders' Equity | ¥ 152.63B | ¥ 147.62B | ¥ 143.75B | ¥ 136.26B | ¥ 137.75B |
| Cash Flow | |||||
| Free Cash Flow | ¥ 25.64B | ¥ -14.07B | ¥ 716.00M | ¥ 7.27B | ¥ 10.35B |
| Operating Cash Flow | ¥ 29.78B | ¥ -11.08B | ¥ 2.58B | ¥ 9.25B | ¥ 13.34B |
| Investing Cash Flow | ¥ -19.65B | ¥ 315.00M | ¥ -5.85B | ¥ -2.63B | ¥ -7.89B |
| Financing Cash Flow | ¥ -5.37B | ¥ -8.84B | ¥ -5.66B | ¥ -6.99B | ¥ -8.13B |
Currency in JPY
